Please assess the completion status of the following clinical trial:

Trial Title: Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA - Recipients:~Group A: Subjects at high risk for transplant related complications and mortality as defined below:~Ages 10 to 75 (both inclusive) with a history of one of the following:~* Treatment with dose intensive chemotherapy and/or radiotherapy~* Previous history of allo/auto transplant~* History of multiple myeloma or extramedullary plasmacytoma~* Chronic disease or co-morbid medical condition including subjects with symptoms or signs of significant pulmonary disease, hepatic disease, kidney disease, cardiac disease or disease of other organ systems which would result in increased risk of morbidity or death from a standard myeloablative transplant.~Diseases to be included:~* CML chronic phase~* Acute lymphoblastic leukemia (ALL), all subjects in complete or partial remission.~* AML: AML in first complete or partial remission Exceptions: AML with good risk karyotypes: AML M3 t(15:17), AML M4Eo (inv. 16), AML t(8;21). All AML in second or subsequent complete remission.~* MDS: refractory anemia with excess blasts (RAEB), or chronic myelomonocyte leukemia (CMML).~* Myeloproliferative diseases associated with either cytopenia or uncontrolled proliferation.~* CLL or small lymphocytic lymphoma (SLL) with bulky or progressive disease despite prior treatment with chemotherapy which includes purine analogs.~* NHL~A) Intermediate or high grade relapsed or progressive despite treatment with standard therapy ineligible for autologous PBSC transplant.~B) NHL intermediate or high grade relapsing despite prior autologous transplant.~C) Low grade follicular or small lymphocytic lymphoma (1) high risk patients who have relapsed following conventional chemotherapy, (2) relapsed following autologous marrow or PBSC transplant, or (3) chemo resistant disease.~D) Mantle cell lymphoma~E) NHL intermediate or high grade with concurrent BCL2 and MYC translocations who are at high risk for relapsed and who have low survival with conventional chemotherapy.~* HD, relapsed after prior autologous transplant or after 2 or more combination chemotherapy regimens and ineligible for autologous PBSC transplant.~* EBV driven lymphoproliferative disorders progressing despite standard therapies.~* MM: MM subjects must be between the ages of 8 and 65 (both inclusive)~* Mycosis fungoides, which has been shown to be amenable to allogeneic stem cell transplants.~Group B: (Closed to enrollment Oct 2010) Subjects with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic BMT but where concern for a high procedural mortality with conventional BMT may delay or prevent such treatment.~Ages 8 to 80 (both inclusive) with a history of one of the following~* PNH associated with either life-threatening thrombosis, cytopenia, transfusion dependence or recurrent and debilitating hemolytic crisis.~* Aplastic anemia or PRCA (acquired or congenital) in subjects associated with transfusion dependence and/or neutropenia who are not candidates for or who have failed immunosuppressive therapy~* RA or RARS MDS subjects who have associated transfusion dependence and/or neutropenia.~Ability to comprehend the investigational nature of the study and provide informed consent. The procedure will be explained to subjects age 8-17 years with formal consent being obtained from parents or legal guardian.~Availability of HLA identical or single HLA locus mismatched family donor~INCLUSION CRITERIA - Donor:~HLA identical or single HLA mismatched family donor~Age greater than or equal to 2 up to 80 years old~Weight greater than or equal to 18 kg~Ability of donor or guardian of donor to comprehend the investigational nature of the study and provide informed consent.~EXCLUSION CRITERIA - Recipient - any of the following:~Pregnant or lactating~Group A: age less than 10 or greater than 75 (multiple myeloma age less than 8 or greater than 65);~Group B: Age less than 8 or greater than 80 years.~ECOG performance status of 3 or more (See NIH Bone and Marrow Consortium Supportive Care Guidelines for Allogeneic Hematopoietic Stem Cell Transplant Recipients - http://intranet.cc.nih.gov/bmt/_pdf/ECOG_Karnofsky_Lansky_Scales.pdf)~Psychiatric disorder or mental deficiency severe as to make compliance with the BMT treatment unlikely and making informed consent impossible~Major anticipated illness or organ failure incompatible with survival from PBSC transplant~Diffusion capacity of carbon monoxide (DLCO) less than 40% predicted.~Left ventricular ejection fraction: less than 30%.~Serum creatinine greater than 2.5 mg/dl or creatinine clearance less than 50 cc/min by 24 hr urine collection~Serum bilirubin greater than 4 mg/dl, transaminases greater than 5x upper limit of normal,~Other malignant diseases liable to relapse or progress within 5 years.~EXCLUSION CRITERIA - Donor - any of the following:~Pregnant or lactating~Donor unfit to receive G-CSF and undergo apheresis (uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia)~HIV positive donor. Donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or human T-cell lymphotropic virus (HTLV I/II) will be used at the discretion of the investigator following counseling and approval from the recipient

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Donor (Type: OTHER): The HLA matched donor will receive granulocyte colony-stimulating factor (G-CSF) with apheresis collections of PBPC on day 5 and day 6 if required. G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
- Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality (Type: EXPERIMENTAL): Participants at high risk for transplant related complications and mortality will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m\^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
- Group B: Stem Cell Transplant in Debilitating Hematologic Diseases (Type: EXPERIMENTAL): Participants with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic Bone Marrow Transplant (BMT) but where concern for a high procedural mortality with conventional BMT will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m\^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver \>5x10\^6 CD34+ cells/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete